Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PTPRA | P18433 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13328152 | 0.81 | KDM4E (0.34) | KDM4EMEN1ALDH1A1GAAMAPT | |
| SCHEMBL13360470 | 0.75 | HSD17B10 (0.36) | KDM4EMEN1ALDH1A1GAAMAPT | |
| SCHEMBL19359600 | 0.75 | ALDH1A1 (0.33) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL13360484 | 0.73 | ALOX15 (0.35) | KDM4EMEN1ALDH1A1GAAMAPT | |
| SCHEMBL13744155 | 0.69 | ADORA1 (0.38) | PTPN1 | |
| SCHEMBL14226084 | 0.62 | — | — | |
| SCHEMBL13228782 | 0.59 | — | — | |
| SCHEMBL10093816 | 0.56 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL18237752 | 0.56 | GRM5 (0.33) | — | |
| SCHEMBL13328146 | 0.55 | ALOX15 (0.33) | KDM4EMEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399659-B2 | Compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-7718648-B2 | Pyridobenzazepine compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-20090299060-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-7572784-B2 | Compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20080045501-A1 | Pyridobenzazepine compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045501-A1 | Pyridobenzazepine compounds and methods for inhibiting mitotic progression | AURKB, AURKC, AURKA | KDM4E 492/4885MEN1 1012/4885ALDH1A1 3480/4885 |
| US-20090299060-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | AURKC, AURKA, AURKB | KDM4E 774/4885MEN1 717/4885ALDH1A1 3815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.